These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9302183)

  • 1. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer.
    Noldus J; Chen Z; Stamey TA
    J Urol; 1997 Oct; 158(4):1606-9. PubMed ID: 9302183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
    Chen Z; Chen H; Stamey TA
    J Urol; 1997 Jun; 157(6):2166-70. PubMed ID: 9146608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.
    Peter J; Unverzagt C; Krogh TN; Vorm O; Hoesel W
    Cancer Res; 2001 Feb; 61(3):957-62. PubMed ID: 11221890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.
    Mikolajczyk SD; Grauer LS; Millar LS; Hill TM; Kumar A; Rittenhouse HG; Wolfert RL; Saedi MS
    Urology; 1997 Nov; 50(5):710-4. PubMed ID: 9372880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
    J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium.
    Ornstein DK; Englert C; Gillespie JW; Paweletz CP; Linehan WM; Emmert-Buck MR; Petricoin EF
    Clin Cancer Res; 2000 Feb; 6(2):353-6. PubMed ID: 10690510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
    Tajiri M; Ohyama C; Wada Y
    Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
    Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
    BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.
    Prestigiacomo AF; Stamey TA
    J Urol; 1996 Jun; 155(6):1977-80. PubMed ID: 8618301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
    Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
    Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production, analysis, and characterization of reference materials for prostate-specific antigen.
    Garg UC; Howanitz JH; Nakamura RM; Plous RH; Eckfeldt JH
    Arch Pathol Lab Med; 1995 Dec; 119(12):1104-8. PubMed ID: 7503657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
    Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
    Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
    Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
    Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.